Another look at imatinib mesylate.
Strebhardt
Klaus
K
Department of Obstetrics and Gynecology, School of Medicine, J.W. Goethe University, Frankfurt, Germany.
Ullrich
Axel
A
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D016923:Cell Death / Q000187:drug effects; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D006333:Heart Failure / Q000139:chemically induced* / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D051379:Mice; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016315:Proto-Oncogene Proteins c-abl / Q000187:drug effects / Q000378:metabolism; D011743:Pyrimidines / Q000009:adverse effects*; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D016315:Proto-Oncogene Proteins c-abl